Cantor Fitzgerald Upgrades Aerie Pharmaceuticals To Buy

Analysts at Cantor Fitzgerald upgraded Aerie Pharmaceuticals Inc AERI from Hold to Buy. The price target for Aerie Pharmaceuticals is set to $15. Aerie Pharmaceuticals shares have dropped 29.70 percent over the past 52 weeks, while the S&P 500 index has surged 11.15 percent in the same period. Aerie Pharmaceuticals' shares fell 0.10 percent to $10.43 in after-hours trading.